TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34229292

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (Group OF) with dexmedetomidine, esketamine and sevoflurane
Number of subjects: 152

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (Group C) with sufentanil and sevoflurane
Number of subjects: 152

Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (Group C)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (Group OF)
Number of subjects: 152
Study: 35946449

Group type: EXPERIMENTAL
Intervention: KliniTrayTM (radiopaque tissue transfer and X-ray system)
Number of subjects: 117

Group type: COMPARATOR
Intervention: ISO (institutional standard procedure)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Immediate re-excision due to positive SR
Number of subjects: 117
Study: 33947618

Group type: EXPERIMENTAL
Intervention: dp‐ucMGP (dephosphorylated, undercarboxylated matrix Gla protein) levels in AAA cases
Number of subjects: 676

Group type: COMPARATOR
Intervention: dp‐ucMGP (dephosphorylated, undercarboxylated matrix Gla protein) levels in controls
Number of subjects: 676
Study: 32544700

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: BRV 100 mg/day
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: BRV 200 mg/day
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study: 36329920

Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: mHealth with interactivity
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control
Number of subjects: 221
Study: 32994487

Group type: EXPERIMENTAL
Intervention: Multi-strain fermented milk product (1 bottle/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multi-strain fermented milk product (3 bottles/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 96
Study: 33091142

Group type: EXPERIMENTAL
Intervention: Titanium-coated PEEK cages (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated PEEK cages (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 32480401

Group type: EXPERIMENTAL
Intervention: Simple Heron's formula
Number of subjects: 60
Study: 33836807

Group type: EXPERIMENTAL
Intervention: Yijinjing exercise intervention combined with routine rehabilitation therapy (40 min/session, 3 sessions/week for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine rehabilitation therapies (occupational therapy, physical therapy, acupuncture therapy, health education) 5 times a week for 3 months
Number of subjects: 72
Study: 32331366

Group type: EXPERIMENTAL
Intervention: Healthy Children, Healthy Families, Healthy Communities Program (multi-level strategies for obesity prevention)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Healthy Children, Healthy Families, Healthy Communities Program
Number of subjects: 104
Study: 35552197

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (2x10^9 cfu/day for 30 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 33057696

Group type: EXPERIMENTAL
Intervention: Intervention group (machine learning mortality predictions with behavioral nudges)
Number of subjects: 14607

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 14607
Study: 34825728

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 54
Study: 32027620

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus NK cells
Number of subjects: 109

Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus NK cells (TPS 50% or higher)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Multiple courses of NK cell infusion
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Single course of NK cell infusion
Number of subjects: 109
Study: 35794080

Group type: EXPERIMENTAL
Intervention: Test formulation of afatinib dimaleate (40 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference formulation of afatinib dimaleate (40 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study: 32638995

Group type: EXPERIMENTAL
Intervention: Preventive self-care health management program
Number of subjects: 540

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 540
Study: 34789636

Group type: EXPERIMENTAL
Intervention: Night denture (ND) placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without ND placement)
Number of subjects: 0
Study: 33515500

Group type: EXPERIMENTAL
Intervention: Maintenance intravenous gemcitabine (1250 mg/m2 on days 1 and 8, in cycles of 21 days) plus supportive care
Number of subjects: 130

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 130
Study: 33475580

Group type: COMPARATOR
Intervention: Closed reduction and immobilisation (Group-A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Open reduction with internal fixation (Group-B)
Number of subjects: 70
Study: 37002475

Group type: EXPERIMENTAL
Intervention: YOGA-DP (Yoga Programme for T2DM Prevention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 65
Study: 33420185

Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus (3 ml, 20 mg/ml) followed by PRP (3 ml)
Number of subjects: 85

Group type: COMPARATOR
Intervention: PRP (3 ml)
Number of subjects: 85
Study: 32563284

Group type: EXPERIMENTAL
Intervention: Innovative study designs and new methodological approaches to statistical analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current study designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis methods
Number of subjects: 0
Study: 33538094

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 32553394

Group type: EXPERIMENTAL
Intervention: Continuing unilateral ECT with antidepressants
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Switching to bilateral ECT
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention reported
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 18
Study: 36041934

Group type: EXPERIMENTAL
Intervention: Peritoneal fixation (PerFix)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (no fixation)
Number of subjects: 245
Study: 32845090

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 426
Study: 32968171

Group type: EXPERIMENTAL
Intervention: tRNS (100‐500 Hz) over bilateral PPC for 15 minutes at 1.5 mA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study: 35719197

Group type: EXPERIMENTAL
Intervention: Cabbage leaf application for 1-hour duration once a day (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cooling gel pad application for 20 minutes duration once a day (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac gel application 4 times a day (n = 20)
Number of subjects: 40
Study: 34524048

Group type: EXPERIMENTAL
Intervention: Interventions to prevent mother to child transmission of HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care interventions
Number of subjects: 0
Study: 34741815

Group type: EXPERIMENTAL
Intervention: Geriatric assessment intervention (tailored geriatric assessment summary and management recommendations)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Geriatric assessment intervention
Number of subjects: 718

Group type: COMPARATOR
Intervention: Usual care (no geriatric assessment summary or management recommendations)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 718
Study: 35667492

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 0
Study: 616116188

Group type: EXPERIMENTAL
Intervention: Hospital-based DSME plus homecare
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hospital-based DSME
Number of subjects: 180

Group type: COMPARATOR
Intervention: Comparison group (usual care)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hospital-based DSME and Hospital-based DSME plus homecare
Number of subjects: 180
Study: 35081576

Group type: EXPERIMENTAL
Intervention: Integra (ADM + STSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matriderm (ADM + STSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelnac (ADM + STSG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (STSG without ADM)
Number of subjects: 0
Study: 34146476

Group type: EXPERIMENTAL
Intervention: Asymptomatic microscopy-detected infections
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Asymptomatic submicroscopic infections
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Symptomatic infections
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Children aged 5-15 years
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Individuals younger than 5 years
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Individuals 16 years or older
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Mosquito feeding experiments
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Samples from four children
Number of subjects: 531
Study: 32150057

Group type: EXPERIMENTAL
Intervention: Peer worker discharge intervention plus usual care
Number of subjects: 590

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 590
Study: 36030343

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 106
Study: 32085529

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 400 U
Number of subjects: 0

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 240 U
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 400 U (open-label phase)
Number of subjects: 0
Study: 35022754

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK)
Number of subjects: 0
Study: 33736944

Group type: EXPERIMENTAL
Intervention: NMES (Neuromuscular Electrical Stimulation) applied at time of surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device (subtherapeutic electrical stimulation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study: 35121493

Group type: EXPERIMENTAL
Intervention: CXCL16 plasma levels in COVID-19 hospitalized patients
Number of subjects: 115
Study: 34450552

Group type: EXPERIMENTAL
Intervention: idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC)
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by tailored and dose-dense docetaxel (dtD) (dtEC-dtD)
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 2887
Study: 32357913

Group type: EXPERIMENTAL
Intervention: ERAS pathway management
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional management mode
Number of subjects: 400
Study: 36050801

Group type: EXPERIMENTAL
Intervention: Smartphone application PromMera
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 140
Study: 33899526

Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP) plus Hyaluronic Acid (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Autologous Microfragmented Adipose Tissue (AMAT)
Number of subjects: 50
Study: 34895483

Group type: EXPERIMENTAL
Intervention: Adrecizumab (8 mg/kg bodyweight)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adrecizumab
Number of subjects: 150
Study: 32740502

Group type: EXPERIMENTAL
Intervention: 3.0 µg/kg IND
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3.5 µg/kg IND
Number of subjects: 61
Study: 36441845

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 33361553

Group type: EXPERIMENTAL
Intervention: EIT group (n=42)
Number of subjects: 87

Group type: COMPARATOR
Intervention: PV group (n=45)
Number of subjects: 87
Study: 32096064

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chewed or integer prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study: 33243799

Group type: EXPERIMENTAL
Intervention: Computerised decision support system (CDSS) intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 18
Study: 33742520

Group type: EXPERIMENTAL
Intervention: Vitamin K (menadiol diphosphate 5 mg, thrice weekly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32421762

Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration (MDA) for scabies
Number of subjects: 0
Study: 33859155

Group type: EXPERIMENTAL
Intervention: LCP-Tacrolimus (LCPT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Immediate-Release Tacrolimus (IR-Tac)
Number of subjects: 55
Study: 35272418

Group type: EXPERIMENTAL
Intervention: Auxiliary acupuncture device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo acupuncture device
Number of subjects: 0
Study: 32615658

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (once a week for three weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) (two times with seven days interval)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS) (2ml injected two times every seven days)
Number of subjects: 92
Study: 35028992

Group type: EXPERIMENTAL
Intervention: DiabetesFlex (patient-controlled flexible visits using patient-reported, outcome-based telehealth follow-up)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: DiabetesFlex
Number of subjects: 343

Group type: COMPARATOR
Intervention: Standard care (face-to-face visits every 4 months)
Number of subjects: 343
Study: 32000711

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, thrice a day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Gefitinib (250 mg, once a day)
Number of subjects: 43
Study: 35210069

Group type: EXPERIMENTAL
Intervention: Specialized yoga training program in addition to current guideline‐based therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Current guideline‐based therapy alone
Number of subjects: 55
Study: 32781104

Group type: COMPARATOR
Intervention: Pembrolizumab (pembro) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with radiation therapy (pembroRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (pembro and pembroRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pembroRT
Number of subjects: 20
Study: 32819979

Group type: EXPERIMENTAL
Intervention: 12 novel circulating biomarkers added to standard predictors
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Standard predictors only
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Log(calprotectin) and log(cathepsin-S)
Number of subjects: 1998
Study: 35505658

Group type: EXPERIMENTAL
Intervention: Weight-reduction diet with a low glycemic index (D group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weight-reduction diet with a low glycemic index and Lactobacillus rhamnosus supplementation (DP group)
Number of subjects: 40
Study: 33228950

Group type: EXPERIMENTAL
Intervention: 3-month exercise program under physiotherapist supervision followed by independent home-based program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 150
Study: 34171789

Group type: EXPERIMENTAL
Intervention: BGF 320/18/9.6 μg
Number of subjects: 8509

Group type: EXPERIMENTAL
Intervention: BGF 160/18/9.6 μg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: GFF 18/9.6 μg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: BFF 320/9.6 μg
Number of subjects: 8509
Study: 33115408

Group type: EXPERIMENTAL
Intervention: IV propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: IH sevoflurane
Number of subjects: 80
Study: 33985595

Group type: EXPERIMENTAL
Intervention: Multi-donor FMT (capsules containing the fecal microbiota of four sex-matched lean donors)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (saline capsules)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Multi-donor FMT
Number of subjects: 87
Study: 35912158

Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine postoperative pain nursing (Control)
Number of subjects: 58
Study: 33507721

Group type: EXPERIMENTAL
Intervention: hCG plus GnRH agonist (group B)
Number of subjects: 114

Group type: COMPARATOR
Intervention: hCG only (group A)
Number of subjects: 114
Study: 32243644

Group type: EXPERIMENTAL
Intervention: SED-ACT (sedentary time interrupted with 2 minutes of moderate-intensity arm crank ergometer physical activity every 20 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: SED (uninterrupted sedentary time)
Number of subjects: 14
Study: 32851885

Group type: EXPERIMENTAL
Intervention: OS nomogram incorporating age, race, histologic grade, AJCC stage, metastasis, surgery, chemotherapy, and tumor size.
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: CSS nomogram
Number of subjects: 1149
Study: 34030331

Group type: EXPERIMENTAL
Intervention: Forage allowance of 12% LW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forage allowance of 16% LW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forage allowance of 8% LW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forage allowance of 4% LW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forage allowance of 8–12% LW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing forage allowance
Number of subjects: 0
Study: 32858860

Group type: EXPERIMENTAL
Intervention: Single-strain probiotics
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Three-strain probiotics
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 39
Study: 33214244

Group type: EXPERIMENTAL
Intervention: 10 mg emixustat
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg emixustat
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2.5 mg emixustat
Number of subjects: 23
Study: 32480307

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 35191169

Group type: EXPERIMENTAL
Intervention: Open-label trials
Number of subjects: 86

Group type: COMPARATOR
Intervention: Open-label arm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Open-label design
Number of subjects: 86
Study: 33677400

Group type: COMPARATOR
Intervention: 12L:12D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 14L:10D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 16L:8D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 18L:6D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 20L:4D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ≥16 h photoperiods
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 16L:8D and 18L:6D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 20-hour photoperiod
Number of subjects: 300
Study: 32926814

Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (RHB-105)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin + omeprazole
Number of subjects: 0
Study: 34020852

Group type: EXPERIMENTAL
Intervention: Shod walking
Number of subjects: 74

Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Outdoor walking
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 74
Study: 34059916

Group type: COMPARATOR
Intervention: Control (9 hours sleep opportunities)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 hours sleep opportunities)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sleep restriction with weekend recovery sleep (5 days insufficient sleep, 2 days ad libitum weekend recovery sleep)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study: 32618626

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (HFNO) during apnea
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-Flow Nasal Oxygen (HFNO) during spontaneous ventilation (SV)
Number of subjects: 20
Study: 32459377

Group type: EXPERIMENTAL
Intervention: FACT-G7 intervention
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 461
Study: 35766022

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33811477

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 62
Study: 32277954

Group type: EXPERIMENTAL
Intervention: Maggot excretions/secretions (ES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of miR-18a/19a or overexpression of TSP-1
Number of subjects: 0
Study: 35156999

Group type: EXPERIMENTAL
Intervention: Closed-Loop Spinal Cord Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open-Loop Spinal Cord Stimulation
Number of subjects: 0
Study: 33104449

Group type: EXPERIMENTAL
Intervention: Depletive DMTs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sequestrating DMTs
Number of subjects: 45
Study: 36244398

Group type: EXPERIMENTAL
Intervention: Bemarituzumab (15 mg/kg bodyweight) plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155